GenapSys, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GenapSys, Inc. - overview
Established
2010
Location
Redwood City, CA, US
Primary Industry
Biotechnology
About
Founded in 2010 and based in California, US, Genapsys, Inc. operates as a biotechnology company that develops a novel DNA sequencing technology and detection system for applied genomic testing and medical sequencing. Hesaam Esfandyarpour is the CEO, chairman, and founder of the company. In May 2021, the firm raised USD 70 million in Series D funding from Farallon Capital Management, PBM Capital Group, and Soleus Capital Management.
The company provides GenapSys™ Sequencer, an electrical-based platform that enables to detect sequencing. This DNA-sequencing technology is used for research and testing genetic diseases, cancer, and microbes. The organization's platform enables academic and clinical researchers, molecular pathologists, and other physicians to gain easy access to genomic sequencing. GenapSys plans to use the May 2021 funding to continue advancing its semiconductor-based NGS platform.
Current Investors
Foresite Capital, Oxford Finance, National Human Genome Research Institute
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Diagnostic Equipment
Website
www.genapsys.com
Verticals
Manufacturing
Company Stage
Ceased Operations
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.